SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Depotech(depo)
DEPO 7.300+1.7%Aug 14 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: chirodoc who wrote (280)11/30/1997 9:42:00 PM
From: Tom D  Read Replies (4) of 887
 
<<<-i would recommend amgen>>>

Chirodoc, have you been able to resolve the Transkaryotic Therapies (TKTX) challenge to Amgen? Imho, this is why their stock is beaten up.

TKTX has developed a thorough understanding of regulatory DNA sequences- - the "on-off" switches located close to the genes which control synthesis of key proteins. TKT can take switches and insert them into cells and activate or inactivate any gene that they want. Their lead product is erythropoietin. Other products are insulin, G-CSF, growth hormone, TPA, interferons, and factor VIII. They put these switches into cell lines and make these proteins or peptides ex vivo. They then sell the proteins. They are addressing markets worth $10.8 billion per year. As one might expect, they are getting sued a lot.

Best Regards,

Tom D
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News